Mifegyne (Mifepristone)

Mifepristone is a progesterone receptor antagonist. By binding to progesterone receptors in the uterus, it prevents the hormone from maintaining the pregnancy, causing decidual breakdown. The drug also sensitizes the uterus to prostaglandins, which enhances uterine contractions and helps expel the gestational sac.

The dose of Mifegyne is determined by the prescribing clinician based on the specific clinical scenario, gestational age, and local guidelines. Healthcare professionals prescribe the appropriate tablet strength and schedule, and patients should follow the prescriber's instructions exactly.

Mifegyne is classified as Pregnancy Category X, meaning it is contraindicated in ongoing pregnancy except for its intended use in termination. It should not be used during breastfeeding because mifepristone can be excreted in breast milk and may affect the infant.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Mifegyne (mifepristone) is the standard antiprogestogen used in combination with misoprostol for early medical termination. Compared with surgical methods, it offers a non‑invasive option with high efficacy up to 10 weeks. Alternative drugs, such as methotrexate, are less commonly used for this indication and have different safety profiles.

Mifegyne tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mifegyne is taken orally as a tablet. The prescriber determines the exact dosage and timing, which is usually followed by a dose of misoprostol taken later to complete the termination process. Administration should occur under medical supervision with appropriate follow‑up.

Serious risks include heavy or prolonged vaginal bleeding, severe infection (sepsis) after incomplete evacuation, allergic reactions including anaphylaxis, and, rarely, uterine rupture. Patients should seek immediate medical attention if they experience excessive bleeding, fever, severe abdominal pain, or signs of an allergic reaction.

Mifegyne should not be used in patients with confirmed ectopic pregnancy, chronic adrenal insufficiency, severe anemia, uncontrolled cardiovascular disease, or those taking anticoagulant therapy that cannot be safely managed. It is also contraindicated in individuals with known hypersensitivity to mifepristone or any tablet excipients.